menu search

Apogee announces first participants dosed ahead of schedule in phase 1 trial of apg777, its novel half-life extended anti-il-13 antibody for the treatment of atopic dermatitis and other inflammatory d

Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two-...

August 7, 2023, 11:30 am

Annexon highlights recent pipeline and business progress and reports second quarter 2023 financial results

ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regu...

August 7, 2023, 10:30 am

Gbpusd daily analysis – august 7, 2023

GBPUSD experienced a rebound from the 1.2619 level after being contained by the support at 1.2590. However, it is important to note that as long as th...

August 7, 2023, 9:04 am

Gbp/usd: failure to defend 1.2600/1.2570 could mean risk of a deeper drop – socgen

GBP/USD has embarked on a phase of pullback after facing stiff resistance near the upper limit of a mul...

August 7, 2023, 8:59 am

Eurusd daily analysis – august 7, 2023

EURUSD is currently encountering the resistance of the falling trend line on the 4-hour chart. As long as the price remains below the trend line resis...

August 7, 2023, 8:37 am

Nektar rallies after releasing new data for rezpeg after eli lilly got it wrong

Nektar Therapeutics (NASDAQ:NKTR) shares rallied more than 15% in Monday pre-market trading after the company released new efficacy data from ...

August 7, 2023, 8:10 am

Eur/usd seems to have moved into a consolidative phase – uob

EUR/USD comes under some selling pressure and is undermined by reviving USD demand. Bets for more Fed rate hikes turn out to be a key factor lending s...

August 7, 2023, 6:14 am

Nanophase technologies corporation (nanx) q2 2023 earnings call transcript

Nanophase Technologies Corporation (OTC:NANX) Q2 2023 Earnings Conference Call August 3, 2023 11:00 AM ...

August 5, 2023, 12:39 pm

Usdcad weekly analysis – august 5, 2023

USDCAD is currently confronting the resistance of the falling trend line on the weekly chart. As long as the price remains below the trend line resist...

August 5, 2023, 4:01 am

Usdjpy weekly analysis – august 5, 2023

USDJPY is within a rising price channel on the weekly chart, and it remains in a long-term uptrend from 127.21. The recent pullback from 145.06 can be...

August 5, 2023, 3:57 am

Audusd weekly analysis – august 5, 2023

AUDUSD has been trading in a sideways range between 0.6170 and 0.7157 for several weeks. The sideways movement is likely a consolidation ...

August 5, 2023, 3:55 am

Gbpusd weekly analysis – august 5, 2023

GBPUSD is in a long-term uptrend from 1.0352, and the pullback from 1.3141 can be seen as a consolidation phas...

August 5, 2023, 3:52 am

Eurusd weekly analysis – august 5, 2023

EURUSD is in a long-term uptrend from 0.9535, and the price action from 1.1032 can be seen as a consolidation ...

August 5, 2023, 3:48 am

Grab is showing inelastic demand in a moat-discovering phase: path to profitability

Grab's cost-cutting and optimization policies not only improved profitability but also revealed a certain degree of moat, inelastic demand, the incent...

August 5, 2023, 2:45 am

Enphase energy's metrics are mixed after guidance miss pulls down shares

Enphase Energy's (US:ENPH) shares have cratered in recent days after the solar inverter maker's second ...

August 5, 2023, 1:25 am

Bitcoin could fall to this level by september; tradecurve pumps by 150%

While market analysts are forecasting a potential dip for Bitcoin by September, Tradecurve is making waves during its presale ...

August 4, 2023, 9:14 pm

Bitcoin loses mojo after first-half rally fails to reignite enthusiasm

Chalk it up to the heat, to late-summer doldrums, or to the phases of the moon, but the usually volatile Bitcoin hasn’t been acting in its typical s...

August 4, 2023, 6:59 pm

Jpmorgan chief economist no longer expects a us recession

JPMorgan economists now no longer expect a US recession 'this calendar year'. This is one of those instances where it becomes abundantly clear that th...

August 4, 2023, 5:52 pm

Astrazeneca is a premium growth story says broker

AstraZeneca second indicated to 2023 with eight different medicines delivering over US$1 billion in sales in the first half, notes Shore Capital. AZN ...

August 4, 2023, 10:44 am


Search within

Pages Search Results: